Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B
December 6, 2021
Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.
- Buyers
- Cyrus Biotechnology, Inc.
- Targets
- Orthogonal Biologics
- Industry
- Biotechnology
- Location
- Illinois, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ligand Pharmaceuticals Acquires Crystal Bioscience
October 4, 2017
Biotechnology
Ligand Pharmaceuticals acquired Crystal Bioscience for $25 million in cash plus up to $10.5 million in milestones and revenue sharing, adding Crystal's chicken-derived HuMab (OmniChicken) antibody discovery platform and an in-house discovery lab. The acquisition (closing announced Oct 4, 2017) brings four fully-funded partnership programs, is expected to be accretive to revenue and earnings, and expands Ligand's OmniAb platform capabilities.
-
Bruker Corporation Acquires biocrates life sciences ag
June 3, 2025
Biotechnology
Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.
-
Bruker Corporation Acquires Canopy Biosciences, LLC
September 11, 2020
Biotechnology
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
-
ORHub, Inc. Acquires PUR Biologics, LLC
April 25, 2022
Medical Devices
ORHub, Inc. (OTC: ORHB) purchased 100% of the equity interest and assets of PUR Biologics, LLC, acquiring proprietary regenerative therapeutic and bone regeneration product technologies. The acquisition enables ORHub to enter the global medical device market and expand its regenerative therapeutic capabilities as it updates corporate branding and prepares for an audit and potential up-listing.
-
Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.
January 29, 2021
Biotechnology
Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.